Lexeo Therapeutics, Inc. Common Stock
$4.50
-0.22%Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -2.4).
Valuation inputs: P/E -2.4, earnings yield N/A, momentum -0.2%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -40.5%, ROIC -42.9%).
Profitability stack: net margin 0.0%, ROE -40.5%, ROIC -42.9%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +8.2%, momentum -0.2%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Lexeo Therapeutics, Inc. Common Stock Market vs Earnings Trajectory
Loading price and EPS data...
Lexeo Therapeutics, Inc. Common Stock Fair Value Envelope
Lexeo Therapeutics, Inc. Common Stock Profit Bridge
Profitability Analysis
Lexeo Therapeutics, Inc. Common Stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Lexeo Therapeutics, Inc. Common Stock Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Lexeo Therapeutics, Inc. Common Stock Street Expectations Map
Wall Street analysts project that LXEO stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 18.33, with estimates ranging from a low of 10.00 to a high of 25.00.
The consensus 1-year price target stands at 18.33, with estimates ranging from a low of 10.00 to a high of 25.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Lexeo Therapeutics, Inc. Common Stock Insider Positioning
During the last 12 months, insiders have purchased $685K and sold $495K worth of LXEO shares, resulting in $190K of net buying activity.
3 Months
0
0.00
59.6K
336.67K
-337K
-$337K
3-6 Months
0
0.00
13.2K
84.22K
-84K
-$84K
6-9 Months
2.2K
5.80K
3.7K
34.31K
-29K
-$29K
9-12 Months
162.5K
679.24K
7.8K
39.89K
+639K
+$639K
Top Buyers
Cooperstone Brenda
Director
$105K
Cholmondeley Paula H
Director
$105K
Altschuler Steven
Director
$105K
Agger Mette Kirstine
Director
$105K
Diaz Reinaldo M
Director
$105K
Top Sellers
Townsend Richard Nolan
Director, Officer: Chief Executive Officer
$420K
Otero Jose Manuel
Officer: Chief Operating Officer
$53K
Adler Eric
Officer: Chief Medical Officer
$9K
Robertson Jenny
Officer: Chief Legal Officer
$8K
See Tai Sandi
Officer: Chief Development Officer
$6K
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $190K net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
No Dividend Yield Data
LXEO has not reported any dividend yield values in the available annual periods.
lxeo Dividend History
Learning Layer
Related Guides
Build conviction on LXEO by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.